suPAR is a biomarker and therapeutic target for AKI

More Details

More Details

Catalytic iron is a biomarker

and therapeutic target in AKI

More Details

A common genetic variant in HO-1 predicts risk of AKI following cardiac surgery

More Details

Immune checkpoint inhibitors cause AKI through tubulo-interstitial nephritis

More Details

FGF23 is an early marker of AKI and death after cardiac surgery and in critically ill patients.


An overview of our projects


A portfolio with a list of our publications


Get to know more about the PI


Get to know more about our team

The Leaf Lab conducts patient-oriented research in acute kidney injury (AKI) and critical illness. Our goal is to develop novel approaches to prevent AKI, and to improve outcomes in patients who suffer from AKI. Read more about AKI.

Our research is highly collaborative and interdisciplinary and includes:

•  Randomized trials
•  Biomarker studies
•  Genetics
•  Epidemiology


Match Day

March 19, 2021

Congratulations to Harkarandeep Singh for matching to Rochester General Hospital for Internal Medicine.

Top Paper Award

January 27, 2021
Shruti Gupta’s paper entitled, “AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19” was selected as one of the top 5 original research papers published in J Am Soc Nephrol in 2020.

NIH R01 Grant

September 1, 2020
David Leaf was awarded an R01 grant from the NIH/NIDDK for his proposal entitled, “Deferoxamine for the Prevention of Acute Kidney Injury.”

NIH R01 Grant

May 1, 2019
David Leaf was awarded an R01 grant from the NIH/NHLBI for his proposal entitled, “Precision Medicine Approach to Vitamin D3 Administration in Critically Ill Patients.”

Gottschalk Grant

July 1, 2018
David Leaf was awarded a Carl W. Gottschalk Research Scholar Grant to study, “Hepcidin, Dysregulated Iron Homeostasis, and Anemia in Human AKI” from the American Society of Nephrology Foundation for Kidney Research.